259 related articles for article (PubMed ID: 32653388)
1. Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy.
Lin CL; Tseng KC; Chen KY; Liao LY; Kao JH
J Formos Med Assoc; 2020 Oct; 119(10):1483-1489. PubMed ID: 32653388
[TBL] [Abstract][Full Text] [Related]
2. Liver transplantation for hepatitis B virus: Decreasing indication and changing trends.
Al-Hamoudi W; Elsiesy H; Bendahmash A; Al-Masri N; Ali S; Allam N; Al Sofayan M; Al Bahili H; Al Sebayel M; Broering D; Saab S; Abaalkhail F
World J Gastroenterol; 2015 Jul; 21(26):8140-7. PubMed ID: 26185387
[TBL] [Abstract][Full Text] [Related]
3. [Risk factors for the development of liver cancer in patients with hepatitis B-related liver cirrhosis treated with long-term nucleos(t)ide analogues].
Zang WW; Su MH; Ling XZ; Wang RM; Cao BC; Wu YL; Deng DL; Wei HL; Liang XS; Jiang JN
Zhonghua Gan Zang Bing Za Zhi; 2020 Aug; 28(8):679-685. PubMed ID: 32911907
[No Abstract] [Full Text] [Related]
4. Long-term prognosis with or without nucleot(s)ide analogue therapy in hepatitis B virus-related decompensated cirrhosis.
Kumada T; Toyoda H; Yasuda S; Miyake N; Ito T; Tanaka J
J Viral Hepat; 2021 Mar; 28(3):508-516. PubMed ID: 33306854
[TBL] [Abstract][Full Text] [Related]
5. The clinical effect of antiviral therapy in patients with hepatitis B virus-related decompensated cirrhosis and undetectable DNA.
Lee HA; Lee YS; Jung YK; Kim JH; Yim HJ; Yeon JE; Seo YS; Lee JS; Lee HW; Kim BK; Park JY; Kim DY; Ahn SH; Kim SU
J Gastroenterol Hepatol; 2023 May; 38(5):716-723. PubMed ID: 36681856
[TBL] [Abstract][Full Text] [Related]
6. Comparison of telbivudine efficacy in treatment-naive patients with hepatitis B virus-related compensated and decompensated cirrhosis in 96 weeks.
Yang X; Li J; Zhou L; Liu J; Wang J; Lu W
Eur J Gastroenterol Hepatol; 2014 Apr; 26(4):396-403. PubMed ID: 24569820
[TBL] [Abstract][Full Text] [Related]
7. Antiviral drug resistance increases hepatocellular carcinoma: a prospective decompensated cirrhosis cohort study.
Li L; Liu W; Chen YH; Fan CL; Dong PL; Wei FL; Li B; Chen DX; Ding HG
World J Gastroenterol; 2013 Dec; 19(45):8373-81. PubMed ID: 24363530
[TBL] [Abstract][Full Text] [Related]
8. Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: comparison between compensated and decompensated cirrhosis.
Kim SS; Hwang JC; Lim SG; Ahn SJ; Cheong JY; Cho SW
Am J Gastroenterol; 2014 Aug; 109(8):1223-33. PubMed ID: 24890440
[TBL] [Abstract][Full Text] [Related]
9. Hepatitis Flares Are Associated With Better Outcomes Than No Flare in Patients With Decompensated Cirrhosis and Chronic Hepatitis B Virus Infection.
Chang ML; Cheng JS; Chien RN; Liaw YF
Clin Gastroenterol Hepatol; 2020 Aug; 18(9):2064-2072.e2. PubMed ID: 31982607
[TBL] [Abstract][Full Text] [Related]
10. Entecavir and Low Genetic Barrier Antiviral Agents for Hepatocellular Carcinoma in Hepatitis B Viral Cirrhosis: Propensity Score Matching.
Li T; Qu Y; Wang Y; Lin C; Yang B; Wang L
J Coll Physicians Surg Pak; 2019 Apr; 29(4):317-323. PubMed ID: 30925952
[TBL] [Abstract][Full Text] [Related]
11. Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients.
Su TH; Hu TH; Chen CY; Huang YH; Chuang WL; Lin CC; Wang CC; Su WW; Chen MY; Peng CY; Chien RN; Huang YW; Wang HY; Lin CL; Yang SS; Chen TM; Mo LR; Hsu SJ; Tseng KC; Hsieh TY; Suk FM; Hu CT; Bair MJ; Liang CC; Lei YC; Tseng TC; Chen CL; Kao JH;
Liver Int; 2016 Dec; 36(12):1755-1764. PubMed ID: 27634134
[TBL] [Abstract][Full Text] [Related]
12. Incidence of hepatocellular carcinoma in chronic hepatitis B virus infection in those not meeting criteria for antiviral therapy.
Alshuwaykh O; Daugherty T; Cheung A; Goel A; Dhanasekaran R; Ghaziani TT; Ahmed A; Dronamraju D; Kumari R; Kwong A; Nguyen M; Kim WR; Kwo PY
Hepatol Commun; 2022 Nov; 6(11):3052-3061. PubMed ID: 36004713
[TBL] [Abstract][Full Text] [Related]
13. Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents.
Kim CH; Um SH; Seo YS; Jung JY; Kim JD; Yim HJ; Keum B; Kim YS; Jeen YT; Lee HS; Chun HJ; Kim CD; Ryu HS
J Gastroenterol Hepatol; 2012 Oct; 27(10):1589-95. PubMed ID: 22554121
[TBL] [Abstract][Full Text] [Related]
14. Forty-eight-week retrospective study of telbivudine and lamivudine treatment in patients with hepatitis B-related cirrhosis.
Han Z; Shi Y; Zhu J; Chen Y; Yin F; Xia L; Luo G; Gao Z; Liu J; Jia G; Li C; Zhou X; Han Y
J Viral Hepat; 2013 Apr; 20 Suppl 1():58-64. PubMed ID: 23458526
[TBL] [Abstract][Full Text] [Related]
15. Long term outcome of antiviral therapy in patients with hepatitis B associated decompensated cirrhosis.
Ju YC; Jun DW; Choi J; Saeed WK; Lee HY; Oh HW
World J Gastroenterol; 2018 Oct; 24(40):4606-4614. PubMed ID: 30386110
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis.
Shim JH; Lee HC; Kim KM; Lim YS; Chung YH; Lee YS; Suh DJ
J Hepatol; 2010 Feb; 52(2):176-82. PubMed ID: 20006394
[TBL] [Abstract][Full Text] [Related]
17. Virological suppression does not prevent the development of hepatocellular carcinoma in HBeAg-negative chronic hepatitis B patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: results of the nationwide HEPNET. Greece cohort study.
Papatheodoridis GV; Manolakopoulos S; Touloumi G; Vourli G; Raptopoulou-Gigi M; Vafiadis-Zoumbouli I; Vasiliadis T; Mimidis K; Gogos C; Ketikoglou I; Manesis EK;
Gut; 2011 Aug; 60(8):1109-16. PubMed ID: 21270118
[TBL] [Abstract][Full Text] [Related]
18. Clinical features and outcomes of hepatocellular carcinoma in Caucasian cirrhotic patients on long-term analogue therapy for hepatitis B.
Loglio A; Iavarone M; Grossi G; Viganò M; Rumi MG; Facchetti F; Lunghi G; Sangiovanni A; Colombo M; Lampertico P
Aliment Pharmacol Ther; 2018 Aug; 48(4):431-439. PubMed ID: 29920698
[TBL] [Abstract][Full Text] [Related]
19. The long-term benefits of nucleos(t)ide analogs in compensated HBV cirrhotic patients with no or small esophageal varices: A 12-year prospective cohort study.
Lampertico P; Invernizzi F; Viganò M; Loglio A; Mangia G; Facchetti F; Primignani M; Jovani M; Iavarone M; Fraquelli M; Casazza G; de Franchis R; Colombo M
J Hepatol; 2015 Nov; 63(5):1118-25. PubMed ID: 26100495
[TBL] [Abstract][Full Text] [Related]
20. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
Jang JW; Choi JY; Kim YS; Yoo JJ; Woo HY; Choi SK; Jun CH; Lee CH; Sohn JH; Tak WY; Lee YR; Han KH
Clin Gastroenterol Hepatol; 2018 Dec; 16(12):1954-1963.e3. PubMed ID: 29753085
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
